Giuseppe Tonini focuses on Internal medicine, Oncology, Colorectal cancer, Cancer and Cancer research. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Endocrinology and Surgery. The Oncology study combines topics in areas such as Hazard ratio, Survival analysis, Survival rate and FOLFIRI.
His work is dedicated to discovering how Colorectal cancer, Clinical trial are connected with Progression-free survival, Chemotherapy regimen, Placebo and Trastuzumab and other disciplines. The various areas that Giuseppe Tonini examines in his Cancer study include Prospective cohort study, Pathology, Immunology and Genotype. Giuseppe Tonini has researched Cancer research in several fields, including Bone metastasis, Breast cancer, Metastasis, Prostate cancer and Cell cycle.
His primary areas of study are Internal medicine, Oncology, Cancer, Colorectal cancer and Surgery. Giuseppe Tonini regularly ties together related areas like Gastroenterology in his Internal medicine studies. His Lung cancer study in the realm of Oncology connects with subjects such as In patient.
His work deals with themes such as Zoledronic acid, Cancer research, Bone disease and Pathology, which intersect with Cancer. His research integrates issues of Regimen, Fluorouracil and Phases of clinical research in his study of Colorectal cancer. His studies deal with areas such as KRAS and Epidermal growth factor receptor as well as Cetuximab.
Giuseppe Tonini spends much of his time researching Internal medicine, Oncology, Cancer, Colorectal cancer and Chemotherapy. Giuseppe Tonini merges Internal medicine with In patient in his research. His Oncology research integrates issues from Bevacizumab, Cetuximab, Nivolumab and Disease.
His work focuses on many connections between Cancer and other disciplines, such as Cancer research, that overlap with his field of interest in Carcinogenesis. His work in Colorectal cancer covers topics such as Phases of clinical research which are related to areas like Temozolomide. His research in Chemotherapy intersects with topics in Gastroenterology and Lung.
Giuseppe Tonini mainly investigates Internal medicine, Oncology, Cancer, Colorectal cancer and Regimen. His study in Internal medicine concentrates on Breast cancer, Clinical trial, Prostate cancer, Concomitant and Cancer pain. His Oncology research is multidisciplinary, incorporating elements of Cetuximab, Nivolumab and Metastatic breast cancer.
His Cancer research is multidisciplinary, relying on both Cancer research, Gut Epithelium, Dysbiosis and Immune system. In his study, Clinical endpoint, Capecitabine, Metronomic Chemotherapy and Temozolomide is strongly linked to Phases of clinical research, which falls under the umbrella field of Colorectal cancer. His study in Regimen is interdisciplinary in nature, drawing from both Bevacizumab and FOLFOXIRI.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter.
Lancet Oncology (2010)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis;Chiara Cremolini;Gianluca Masi;Sara Lonardi.
The New England Journal of Medicine (2014)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini;Fotios Loupakis;Carlotta Antoniotti;Cristiana Lupi.
Lancet Oncology (2015)
Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr).
E. Cacciari;S. Milani;Antonio Balsamo;E. Spada.
Journal of Endocrinological Investigation (2006)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis;A Ruzzo;C Cremolini;B Vincenzi.
British Journal of Cancer (2009)
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
R. Gralla;M. Lichinitser;S. Van der Vegt;H. Sleeboom.
Annals of Oncology (2003)
PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
Fotios Loupakis;Luca Pollina;Irene Stasi;Annamaria Ruzzo.
Journal of Clinical Oncology (2009)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge.
Lancet Oncology (2017)
Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients
Daniele Santini;Bruno Vincenzi;Giordano Dicuonzo;Giuseppe Avvisati.
Clinical Cancer Research (2003)
Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy
Annamaria Ruzzo;Francesco Graziano;Fotios Loupakis;Eliana Rulli.
Journal of Clinical Oncology (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: